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Abstract
Importance—Patients with 22q11.2 deletion syndrome (22q11DS) have an elevated (25%) risk 
for developing schizophrenia. Recent reports have suggested that a subgroup of children with 
22q11DS display a substantial decline in cognitive abilities, starting at a young age.
Objective—To determine whether early cognitive decline is associated with risk of psychotic 
disorder in 22q11DS.
Design, setting and participants—As part of an international research consortium initiative, 
we used the largest dataset of intelligence (IQ) measurements in subjects with 22q11DS reported 
to date in order to investigate longitudinal IQ trajectories and the risk of subsequent psychotic 
illness. A total of 829 subjects with a confirmed hemizygous 22q11.2 deletion, recruited through 
12 international clinical research sites, were included. Both psychiatric assessment and 
longitudinal IQ measurements were available for a subset of 411 subjects (388 with ≥1 assessment 
at age 8 to 24 years).
Main outcome measures—Diagnosis of a psychotic disorder, longitudinal IQ trajectory and 
initial IQ, as well as timing of the last psychiatric assessment with respect to the last IQ test.
Results—On average, children with 22q11DS showed a mild decline in full scale IQ (7 points) 
with increasing age, particularly in the domain of verbal IQ (9 points). In those who developed 
psychotic illness (47/388) this decline was significantly steeper (p<0.0001). Those with a negative 
deviation from the average cognitive trajectory observed in 22q11DS were at significantly 
increased risk for the development of a psychotic disorder (OR=2.49, 95% CI 1.24–5.00, p=0.01). 
The divergence of verbal IQ trajectories between those who subsequently developed a psychotic 
disorder and those who did not was distinguishable from the age of 11 years onwards.
Conclusions and relevance—In 22q11DS early cognitive decline is a robust indicator of the 
risk of developing a psychotic illness. These findings mirror those observed in idiopathic 
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schizophrenia. The results provide further support for investigations of 22q11DS as a genetic 
model for elucidating neurobiological mechanisms underlying the development of psychosis.
Cognitive decline in schizophrenia is a fundamental component of the illness.1 Importantly, 
this decline is evident years prior to emergence of psychotic symptoms,2–11 indicating that 
the onset of the disease process precedes the emergence of overt symptoms.12 In clinical 
practice, psychosis is a necessary diagnostic criterion prompting initiation of treatment. The 
time lag between onset of the disease process and diagnosing schizophrenia is a major 
challenge for research into early phases of the disorder. Given the prevalence of 
schizophrenia (~1%), large samples are required to establish the association of early 
phenotypic changes with subsequent development of psychosis.
The 22q11.2 deletion syndrome (22q11DS) offers a valuable model to study risk 
mechanisms for schizophrenia. Approximately 25% of patients with 22q11DS develop 
schizophrenia,13–16 making the associated hemizygous 1.2–3Mb deletion on the long arm of 
chromosome 2217,18 the strongest single genetic risk factor for the disorder.19 The core 
phenotype of schizophrenia in 22q11DS, including the neurocognitive profile, is similar to 
that of schizophrenia in the general population.20,21
22q11DS patients perform worse on neurocognitive tests such as verbal memory22 and 
spatial working memory23 after the onset of psychosis compared to those without psychosis. 
Psychotic disorder was associated with a deterioration of social and academic skills24 as 
well as a deficit of approximately eight intelligence quotient (IQ) points25 in cross-sectional 
studies, while previous longitudinal studies suggest that loss of cognitive skills, especially 
verbal IQ (VIQ), precedes the emergence of psychosis.26–28 Such findings are consistent 
with observations of schizophrenia in the general population.2–11,29 Although some decline 
relative to population norms – i.e. developmental lag - is expected in children in the lower 
IQ range,30–32 a recent prospective longitudinal study found that about one-third of children 
with 22q11DS under age 10 not only display cognitive deficit relative to age norms, but also 
an absolute decline in cognitive abilities.33 Collectively, these initial studies suggest that in 
patients with 22q11DS, as in the general population, both early cognitive deficits as well as 
early cognitive decline could portend schizophrenia.
This is the first multi-site study on the developmental trajectory of intellectual abilities and 
psychosis in 22q11DS, reporting the largest longitudinal dataset of subjects with 22q11DS 
to date. We hypothesized that cognitive decline observed in children and adolescents with 
22q11DS is associated with subsequent onset of psychotic illness.
Methods
Participants
A sample of 829 subjects with 22q11DS was drawn from the International 22q11DS Brain 
Behavior Consortium, a collaboration of 22 research sites. Data include standardized 
cognitive and psychiatric assessment obtained from ongoing studies. Subjects were selected 
based on availability of: a) IQ measurements obtained with Wechsler intelligence scales 
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(e.g. WPSSI, WISC, WASI or WAIS)34–37, and b) a structured diagnostic interview by a 
trained clinician.
Recruitment & assessment
Subjects were included in studies approved by the local IRB committees and with 
appropriate informed consent. Presence of the 22q11.2 deletion was confirmed by 
established genetic methods. eTables S1 – S3 present the sites, assessment methods and 
demographics. The total data for 829 subjects with 22q11DS generated cognitive 
development charts normative for 22q11DS; we use the term “22q11DS-specific” 
throughout this manuscript to distinguish these from norms derived from the general 
population. The association between IQ trajectory and psychotic disorder was examined in a 
subgroup of 388 subjects with longitudinal data (Figure 1).
Diagnostic categories
We defined psychotic disorder, here termed “psychosis”, as any psychotic spectrum 
disorder, including schizophrenia (n=20), schizoaffective (n=6), schizophreniform (n=3), 
brief psychotic disorder (n=2), delusional disorder (n=2), psychotic disorder not otherwise 
specified (NOS; n=21) and bipolar I disorder with psychotic features (n=1). The relative 
timing of the most recent psychiatric assessment to the last cognitive measurement, pertinent 
to evaluating whether changes in IQ precede the onset of psychosis, is presented in Table 1.
Statistical analysis
Because of the limited number of IQ measures in subjects <8 years and > 24 years, we 
restricted analyses to ages 8–24 years. We performed three analyses (Figure 1):
1. 22q11DS-specific IQ-trajectory charts: IQ data from 829 subjects with 22q11DS 
(389 with one assessment, 440 with >=2 longitudinal assessments) yielded 1164 
observations to construct 22q11DS-specific IQ-trajectories.
2. Cumulative IQ change curves: These analyses required data on psychiatric 
diagnosis and included a subset of 411 subjects with 22q11DS: 388 had at least two 
longitudinal IQ measurements, including one obtained between ages 8–24 years 
(341 without psychosis, 47 with psychosis at the most recent assessment).
3. Calculation of effect size for cognitive decline: This subsample included 326 
subjects with at least two IQ measurements within the age range 8–24 years (281 
without psychosis, 45 with psychosis).
For all analyses we used scaled IQ scores. Since the development and stability of cognitive 
abilities in 22q11DS patients deviates from the general population, we established a 
22q11DS-specific chart for intellectual development in 22q11DS, similar to growth charts 
for patients with this38 and other syndromes.39 Individual IQ measurements were used to 
calculate percentiles for each age stratum. A four-year-bin sliding window was applied to 
enhance accuracy of percentile estimation. Subsequently, percentile points were connected 
to generate percentile lines, which were smoothed using the Bezier curve procedure (R 
script, Supplemental Material). Smoothing percentile lines is a standard procedure in the 
development of normative charts.40
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Change in IQ per year was calculated as the difference in IQ between two measurements 
divided by the number of interval years. For each year (8–24) the mean annualized IQ 
change was calculated (1695 calculated observations, on average 100 per year, with a 
minimum of 19 such observations at 24 years). The mean delta IQ per year of these 
observations (calculated separately for full scale, verbal and performance IQ) was used to 
construct the cumulative IQ trajectory curves.
The cumulative trajectories of IQ change over time are represented separately for those with 
and without psychosis (Figures 3a–c). A bootstrap procedure evaluated at which point the 
95% confidence intervals of the two curves no longer overlapped, indicating a significantly 
different trajectory of the slopes. We performed a regression analysis to estimate the change 
in IQ as a function of age, containing linear and quadratic expressions of age as regressors, 
and allowing full interaction with diagnostic status. Thus, we tested whether the rate of 
linear change differed between subjects with and without psychosis.
Next, we examined the strength of correlation between IQ decline and psychosis risk using 
the 22q11DS-specific chart of average IQ trajectory. We considered the difference in IQ 
percentile between two time points as a categorical variable comparing those with negative 
deviations from the original percentile versus those with no change or increase from the 
original percentile. Subsequently, the proportion of subjects with psychosis was compared 
between those with and without IQ decline according to these categorical definitions. We 
used logistic regression analyses with psychosis as the primary outcome measure and IQ 
percentile decline as the dependent variable. Age at last assessment and gender were 
covariates. Next, IQ at the first measurement was added to the model as a continuous 
variable (and post-hoc as a dichotomized variable using a median split). Finally, we 
examined to what extent the timing of the most recent psychiatric assessment relative to the 
last cognitive measurement could have influenced the results. We performed a post-hoc 
analysis with the time between the last IQ measurement and the time of psychiatric 
assessment as a covariate in the logistic regression model.
Results
The mean age at the most recent psychiatric assessment in subjects with at least 2 IQ 
measurements (n=411, Figure 1) was 16.1 (± SD 6.2) years. The male to female ratio was 
0.9:1 and 55/411 subjects (13.4%) were diagnosed with a psychotic disorder. Baseline IQ 
(i.e. IQ at first cognitive assessment) was lower in this group (FSIQ 65.5 (± SD 12.0), VIQ 
67.5 (± SD 14.7), PIQ 65.0 (± SD 16.9)) compared to those without a psychotic disorder 
(FSIQ 74.0 (± SD 14.0), VIQ 74.8 (± SD 18.6), PIQ 71.8 (± SD 16.6)). Overall, subjects 
showed a decline in IQ over time, particularly in VIQ. The average total declines in 
cognitive abilities (ages 8–24) were 7.0 points (FSIQ), 9.0 points (VIQ) and 5.1 points (PIQ) 
(Figure 2).
There was a significant difference in the slope of IQ trajectories; the psychosis group 
demonstrated a steeper decline than the non-psychosis group (Figure 3a–c). The difference 
was significant for FSIQ and both subscales (p-values < 0.001), but was most pronounced 
for VIQ as illustrated by the larger effect size (partial Eta squared of 0.07 for VIQ, 0.04 for 
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FSIQ and 0.01 for PIQ). The divergence of VIQ trajectories started early (Figure 3a), with 
the 95% CIs of the VIQ trajectories for the two groups calculated with the bootstrap 
procedure not overlapping from age 11 onward. Notably, the average age at onset of the first 
psychosis, estimated from the available clinical records, was 18.1 yrs (95% confidence 
intervals 17.0 – 19.1 yrs) with the youngest age at onset being 12.7 years.
The average age at psychiatric assessment differed between the non-psychosis (15.5±5.8 
yrs.) and psychosis groups (20.1±7.5 yrs.; p<0.001). Importantly, the average age at last 
cognitive assessment followed a similar pattern (16.3±5.7 and 22.2±9.3 yrs., respectively). 
To examine whether a change in IQ precedes the onset of psychosis, the last cognitive 
assessment should be performed before the psychiatric assessment. In our sample, both 
order and interval between the two assessments was variable. However, the proportion of 
22q11DS subjects for whom their last psychiatric assessment preceded their last cognitive 
assessment was comparable between those with (47.3%) and those without psychosis 
(39.9%) (p=0.37, Table 1).
eFigures S1a–c present 22q11DS-specific charts for the trajectory of intellectual 
development. Overall, there is a mild decrease in IQ between ages 8 and 24 years. From age 
20 onwards the number of available observations dropped substantially, limiting the 
accuracy of percentile trajectories.
Although all IQ slopes (FSIQ, VIQ, PIQ) differed significantly between the two 22q11DS 
groups, the most pronounced deviation in trajectory between those with and without 
psychosis was in VIQ. We therefore further examined this measure. Using the 22q11DS-
specific chart, for each subject we assessed whether the results of the second VIQ 
measurement were consistent with or changed from the initial VIQ percentile. eFigure S2 
shows a histogram of the distribution of deviations from VIQ percentile; the curve is skewed 
to the left and the subgroup with psychosis is over-represented in the negative range. We 
therefore defined cognitive decline as a negative deviation from the trajectory expected in 
22q11DS subjects.
Comparing those with and without a decline in VIQ, we found that subjects with VIQ 
decline were more likely to develop a psychotic illness (Table 2: 18.2% vs. 9.8%; OR=2.49, 
95% CI 1.24–5.00, p=0.010) We then examined to what extent low IQ at the first 
measurement could be a risk factor for psychosis. When added to the model, both initial 
VIQ and the VIQ decline were significantly associated with an increased risk for psychosis 
(OR=3.89, 95% CI 1.73–8.75 for decline, p=0.001). When initial IQ measurements alone 
were considered only FSIQ at initial measurement was significantly associated with 
subsequent psychotic illness (p=0.005).
Given this observation, we examined initial IQ as a dichotomous variable in a post-hoc 
analysis, using a definition of potential clinical value. We found that regardless of 
subsequent decline, baseline FSIQ above 75 was associated with lower risk for developing 
psychosis (OR=2.73, 95% CI 1.30–5.73, p=0.008). We assessed the possible influence of 
the time interval between psychiatric and cognitive measurements, covarying for this 
interval in the logistic regression model. The findings maintained, indicating that the 
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difference in IQ trajectories between those with and without psychosis could not wholly be 
attributed to variation of the time interval between the last cognitive and psychiatric 
assessments (data not shown). Also, when restricting the analysis to the subgroup of subjects 
in whom the psychiatric assessment either co-occurred or followed the last cognitive 
measurement (see Table 1) the results were similar (difference in VIQ trajectories between 
those with and those without psychosis: OR=2.56, p=0.026).
Discussion
In the largest study ever conducted of the developmental trajectory of intellectual abilities in 
22q11DS, we found that cognitive decline in subjects with 22q11DS is greater in those who 
develop a psychotic disorder, and this decline appears to start as early as age 11. Those with 
a negative deviation from the average cognitive trajectory observed in 22q11DS had a three-
fold increased risk for the development of a psychotic disorder. This is further support that 
22q11DS provides a unique opportunity to prospectively examine the pathophysiology of 
cognitive decline preceding the onset of psychosis.
Our results also suggest that cognitive decline could potentially become a useful marker in 
the clinical management of youth with 22q11DS. Several studies have reported potential 
markers for psychosis in 22q11DS, including changes in brain anatomy,26,27,41–43 high 
plasma levels of the amino acid proline44–46 and genetic variation at the intact 22q11.2 
allele.47–49 These markers however may be difficult to implement clinically, due to practical 
constraints and/or small effect sizes. Serial cognitive testing in 22q11DS is feasible in 
clinical practice33 and the effect sizes reported here may be clinically meaningful. Although 
independent replication and an understanding of the predictive values of cognitive change at 
the individual level are needed, our findings suggest the potential utility of implementing a 
systematic surveillance of cognitive development in current clinical practice.
Our findings indicate that, regardless of subsequent decline, a relatively low initial IQ 
(below 75) measured at or before the onset of adolescence is, independently, a risk factor for 
psychosis in 22q11DS. This finding is consistent with studies in the general population 
indicating that low IQ increases the risk for schizophrenia8,50 and that this cognitive deficit 
is already apparent by age 13, years before the typical onset of psychosis.51,52
The study of cognition associated with schizophrenia (risk) encompasses different 
concepts,53 including early developmental deficits that may remain stable over time, and 
deficits that emerge during development. Decline observed in cognitive performance may be 
due to the phenomenon of developmental lag where the cognitive growth is insufficient to 
keep up with the development observed in normal peers. Alternatively, cognitive decline 
may also represent an absolute loss of previously acquired cognitive ability. The underlying 
mechanism of the cognitive decline observed in the current study cannot be determined and 
could therefore be related to developmental lag, absolute decline, or both. A previous study 
of 22q11DS subjects indicates that an absolute loss of cognitive abilities is likely to 
contribute to the observed decline.33
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Possibly, low initial IQ and subsequent cognitive decline are two independent phenomena, 
with the former reflecting suboptimal neurodevelopment leading to brain vulnerability to a 
broad range of psychopathology. Indeed, in the general population low IQ increases the risk 
for many neuropsychiatric disorders.50,54–56 Consistently, subjects with 22q11DS have, on 
average, lower cognitive abilities compared to the general population and display a wide 
range of psychiatric disorders.16,57,58 Early cognitive decline may reflect a distinct process 
in this genetic condition, that may be specifically associated with the ensuing psychotic 
disorder. The nature of the association between psychosis and low or decline in IQ cannot be 
inferred from our observations however. It is possible that a deficit and/or decline in 
cognitive abilities render the brain vulnerable to psychosis. Alternatively, both IQ changes 
and psychosis may be manifestations of the same mechanism. Findings from the Dunedin 
birth cohort indicate that both a baseline cognitive deficit, measured at age 7, and a 
subsequent developmental lag in cognitive performance (particularly in domains indexing 
rapid information-processing) between 7 and 13 years are associated with increased risk for 
idiopathic schizophrenia.53 Our results are largely consistent with these observations, 
although in contrast to findings in 22q11DS patients,59 in the Dunedin cohort no evidence 
was found for absolute cognitive deterioration.53 Alternatively, it is possible that some 
subjects with low initial IQ in our sample may have had IQ decline prior to the first 
cognitive measurement. Indeed, cognitive decline in 22q11DS has been observed between 
the ages of 5.5 and 9.5 years,33 and approximately one third of patients who show stable IQ 
after age 9.5 years have shown a decline in cognitive abilities between 7.5 and 9.5 years.60 
The apparent stabilization of the IQ trajectory between ages 16–20 years observed in our 
study (Figures 2, 3) may suggest that IQ decline before age 16 is prodromal while further 
decline after age 18–20 may be related to further cognitive deterioration associated with the 
emergence of psychosis itself and diminishing cognitive reserve.61
Several features make 22q11DS a unique model to study schizophrenia developmentally, 
particularly “the trajectory from risk to disorder”.62 In 22q11DS we have both a high risk for 
psychotic disorders, especially schizophrenia, caused by a specific genetic etiology, and the 
frequent identification of this etiology very early in life thus allowing follow-up across the 
lifespan. The occurrence of cognitive decline prior to the first psychotic episode1,6,63, 
observed in both 22q11DS and idiopathic schizophrenia, strongly suggests that psychosis is 
likely a late symptom of the disease. To increase our understanding of schizophrenia, more 
efforts should be directed towards elucidation of its early cognitive aspects.12 The study of 
patients with 22q11DS provides a valuable contribution to this endeavor.
In particular, one or more genes within the deletion region or elsewhere in the genome may 
be involved in the etiology of both early cognitive decline and the ensuing expression of 
schizophrenia. The relative genetic homogeneity and the high risk of expression of these 
phenotypes in the 22q11DS population contrast with the general population where genetic 
contributions to schizophrenia are highly heterogeneous and risk is much lower. Therefore, 
studying 22q11DS as a genetic model for these phenotypes may facilitate the identification 
of contributing genes. Arguably such genes may also be involved in the etiology of 
cognitive decline and schizophrenia in the general population.
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The study has several limitations. A priori standardization of cognitive and psychiatric 
assessment methods across sites is lacking; however in all subjects the diagnosis of 
psychotic disorders was determined using the same (DSM-IV) classification criteria. 
Moreover, our cognitive data were restricted to those assessed with any of the Wechsler 
scales to optimize comparison over time and across sites. Timing of the psychiatric 
assessment in relation to last IQ testing is critical for discerning whether changes in IQ 
precede psychosis onset. In our dataset the sequence was variable; however in 59% of 
subjects the psychiatric assessment was performed either concurrently or after the last 
cognitive assessment. This proportion was not different between those with and without 
psychosis. Importantly, the observed association between cognitive decline and psychosis 
did not change after inclusion of the time interval between psychiatric and cognitive 
assessment as a covariate. Furthermore, the average estimated age at onset of psychosis was 
18.1 years, 95% CI 17.0–19.1, much later than the age at which the divergence of IQ 
appears (Figure 3a).
In this dataset the best estimate of psychosis onset was the time of the psychiatric 
assessment at which the diagnosis was made. The actual age at onset may differ as a 
function of the delay between the onset of symptoms and the psychiatric evaluation. 
However, 22q11DS patients, given the awareness of the genetically mediated increased risk 
for psychotic disorders, may tend to present for evaluation as soon as behavioral changes 
emerge. Nevertheless, more accurate data on the actual age at onset of psychosis, and 
possibly the use of continuous measures of psychosis, will be valuable for future studies in 
this population. Another limitation is insufficient data to estimate IQ changes beyond age 
24, although there is evidence suggesting further cognitive decline in some adults with 
22q11DS.64 Ongoing data collection in several 22q11DS cohorts will provide such 
information. Finally, no information was available regarding socioeconomic status of the 
subjects.
In many subjects the last psychiatric assessment was performed at a rather young age, 
therefore some children currently without a psychotic disorder diagnosis may later develop 
psychosis. Ideally, the groups with and without psychosis should be matched for age. 
Restricting the sample to age-matched subjects was not feasible due to insufficient power. 
We therefore used age as a covariate in our analyses. Previous studies indicate that 
approximately 25% of patients with 22q11DS develop schizophrenia. In the present study 
only 13.4% had psychosis, and thus a substantial proportion of subjects currently classified 
as “without psychosis” may be, in reality, false negatives. However, as a consequence, the 
IQ trajectory in the “without psychosis” group would be expected to show less decline than 
that observed. Thus, our data are likely to represent a conservative portrayal of the divergent 
IQ trajectories in 22q11DS patients with and without psychosis.
Although our analyses were restricted to subjects assessed with Wechsler scales, in some 
subjects different versions were used. Possibly, those subjects, in particular when a change 
occurred from WISC-III to WAIS, may demonstrate a change in IQ score resulting from 
different normative comparison groups between the two versions. Available evidence 
suggests that in comparison to the WISC, the WAIS tends to result in somewhat higher IQ 
scores65. Therefore, if the use of different Wechsler scales has influenced our results in any 
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way, the changes from WISC to WAIS would be expected to mitigate the overall observed 
average decline in IQ in our 22q11DS patients, rather than to exaggerate it. Importantly, the 
proportion of subjects in whom such a shift in test version occurred at follow-up was similar 
in the “with psychosis” (27%) and “without psychosis”(25%) subgroups, making this 
unlikely to explain the observed difference in IQ trajectories. Notwithstanding these 
limitations, the current study is unprecedented in the large size of the cohort, the prospective 
design and the restriction to one type of intelligence assessment.
Conclusion
Subjects with 22q11DS who develop psychotic disorder show a significant cognitive 
decline, most pronounced in verbal IQ. This decline is significantly steeper than the 
intellectual decline over childhood and adolescence observed in 22q11DS subjects without 
psychosis. Importantly, the IQ trajectories in those with and without a psychotic disorder 
diverge at an early age, several years before the usual onset of psychosis in 22q11DS.16,20,28 
Our observations have potential ramifications for clinical management of 22q11DS patients 
and for understanding the pathophysiology of schizophrenia, especially the importance of 
early cognitive decline preceding the first psychotic episode.
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Figure 1. Flowchart of 22q11DS subjects’ selection steps
No explanatory legend required.
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Fig. 2. Cumulative plot of the mean annual IQ decline per age in 22q11DS (full longitudinal 
sample, Verbal, Performance and Full Scale)
For each year the average change in IQ is calculated and represented cumulatively for FSIQ, 
VIQ and PIQ for all 22q11DS subjects where two or more IQ test results were available 
between ages 8 and 24 years (n=388). Note that this graph is not a longitudinal “average” 
trajectory.
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Fig. 3a–c. Cumulative plot of the mean annual IQ decline per age (Verbal, Performance and Full 
Scale) in 22q11DS, with psychosis vs. without psychosis
For each year the average change in IQ is calculated and represented cumulatively for both 
subgroups (subjects with 22q11DS with and those without a psychotic disorder) where two 
or more IQ test results were available between ages 8 and 24 years (n=388). Note that this 
graph is not a longitudinal “average” trajectory. This implies that the effect size of IQ 
decline between the two groups is not calculated by the absolute difference in IQ at any 
given age, but by the difference in slope. What can be observed is that in the subjects in 
whom a psychotic disorder is diagnosed the decline in IQ is steeper for most age points 
(p<0.001), but most pronounced for VIQ as illustrated by the larger effect size (partial Eta 
squared of 0.07 for VIQ, 0.04 for FSIQ and 0.01 for PIQ).
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Table 1
Timing of psychiatric assessment relative to last cognitive assessment in 411 subjects with 22q11DS, and 
diagnostic classifications for the 55 subjects with psychosis.
Timing of psychiatric diagnosis (DIAGN) versus timing of last cognitive assessment (COGN)
DIAGN before last COGN1 DIAGN at the same time or after last COGN1
n % n %
With psychosis (n=55) 26 47.3 29 52.7
Without psychosis (n=356) 142 39.9 214 60.1
All (n=411) 168 40.9 243 59.1
Diagnostic classification of psychotic disorders (according to DSM-IV criteria)
n %
Schizophrenia 20 35.7
Schizophreniform disorder 3 5.5
Schizoaffective disorder 6 10.9
Delusional disorder 2 3.6
Brief psychotic disorder 2 3.6
Psychotic disorder NOS 21 38.2
Bipolar I disorder (with prominent psychotic symptoms) 1 1.8
Total subjects “with psychosis” 2 55 100.0
1
DIAGN before last COGN: the most recent psychiatric assessment performed more than 3 months prior to the last cognitive assessment. 
DIAGN at the same time or after last COGN: the most recent psychiatric assessment was within 3 months before or after the last cognitive 
assessment, or at any time thereafter.
2
In one subject, who had been previously assessed in direct interviews, the presence of psychosis was subsequently reported by parents by 
telephone.
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